Wall Street brokerages expect Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Rating) to announce earnings per share of ($0.29) for the current quarter, according to Zacks. Zero analysts have made estimates for Kiromic BioPharma’s earnings. Kiromic BioPharma reported earnings per share of ($0.53) during the same quarter last year, which would suggest a positive year over year growth rate of 45.3%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Kiromic BioPharma will report full-year earnings of ($1.45) per share for the current financial year. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Kiromic BioPharma.
Several institutional investors and hedge funds have recently modified their holdings of the company. 1492 Capital Management LLC boosted its stake in shares of Kiromic BioPharma by 21.3% in the third quarter. 1492 Capital Management LLC now owns 434,408 shares of the company’s stock worth $1,334,000 after buying an additional 76,402 shares during the last quarter. Intellectus Partners LLC raised its holdings in Kiromic BioPharma by 32.0% in the 3rd quarter. Intellectus Partners LLC now owns 98,850 shares of the company’s stock worth $303,000 after purchasing an additional 23,950 shares during the period. LPL Financial LLC raised its holdings in Kiromic BioPharma by 59.8% in the 4th quarter. LPL Financial LLC now owns 84,400 shares of the company’s stock worth $129,000 after purchasing an additional 31,600 shares during the period. Zeke Capital Advisors LLC raised its holdings in Kiromic BioPharma by 236.7% in the 3rd quarter. Zeke Capital Advisors LLC now owns 56,899 shares of the company’s stock worth $175,000 after purchasing an additional 40,000 shares during the period. Finally, Geode Capital Management LLC acquired a new position in Kiromic BioPharma in the 3rd quarter worth about $158,000. Hedge funds and other institutional investors own 16.03% of the company’s stock.
About Kiromic BioPharma (Get Rating)
Kiromic BioPharma, Inc, a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy.
- Get a free copy of the StockNews.com research report on Kiromic BioPharma (KRBP)
- ChemoCentryx: A Biotech Stock Well Worth the Risk
- Skechers Stock Can Be Bought on Pullbacks
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.